文献速递慢阻肺肺结节与肺癌

慢阻肺改变非小细胞肺癌免疫细胞组成及免疫检查点抑制剂疗效

Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

该研究对接受非小细胞肺癌(NSCLC)切除的患者行流式细胞术与T细胞受体测序,比较合并与不合并慢阻肺(COPD)者的肺与肿瘤免疫微环境,并用小鼠吸烟模型及免疫检查点抑制剂(ICI)治疗回顾队列分析生存。结果显示COPD患者肺内产生IFN-γ的CD8+与CD4+(Th1)淋巴细胞增多,肿瘤PD-1表达升高,COPD与ICI治疗者无进展生存期延长相关。

要点

  • COPD患者肺与肿瘤微环境中Th1细胞群扩增
  • COPD患者肿瘤PD-1表达升高
  • COPD与ICI治疗者更长无进展生存间期相关

核心结论

  • COPD患者肺和肿瘤微环境中Th1细胞群扩增,且COPD与ICI治疗者较长的无进展生存间期相关。

研究设计与样本

  • 前瞻性队列中接受NSCLC切除的患者,用流式细胞术和T细胞受体测序分析切除的肺与肿瘤组织,比较有无COPD者。
  • 采用小鼠香烟烟雾暴露模型评估对肺部免疫细胞群的影响。
  • 另分析一个接受免疫检查点抑制剂治疗的回顾性队列并量化其生存。

主要发现

  • COPD患者肺内产生IFN-γ的CD8+和CD4+(Th1)淋巴细胞数量增加。
  • 人和小鼠中吸烟暴露均见Th17含量增加,但与COPD的发生或严重程度无关。
  • COPD受累肺组织显示Th1分化增加,并在配对的肿瘤样本中重现。
  • COPD患者肿瘤中PD-1表达增加。
  • COPD的存在与接受ICI治疗患者的无进展生存期相关。

临床怎么用

  • 对合并COPD的NSCLC患者,可关注其肺与肿瘤微环境中Th1细胞群扩增及肿瘤PD-1表达升高。
  • COPD的存在可能提示接受ICI治疗者无进展生存间期较长,可作为评估免疫治疗获益的参考信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Chronic obstructive pulmonary disease (COPD) and non-small cell lung cancer (NSCLC) are interrelated diseases with substantial mortality, and the pathogenesis of both involves aberrant immune functioning. OBJECTIVES: To profile immune cell composition and function in patients with NSCLC and describe the effects of COPD on lung and tumor microenvironments. METHODS: We profiled resected lung and tumor tissue using flow cytometry and T-cell receptor sequencing in patients with and without COPD from a prospective cohort of patients undergoing resection of NSCLC. A murine cigarette smoke exposure model was used to evaluate the effect on pulmonary immune populations. A separate retrospective cohort of patients who received immune checkpoint inhibitors (ICIs) was analyzed, and their survival was quantified. MEASUREMENTS AND MAIN RESULTS: We observed an increased number of IFN-γ-producing CD8+ and CD4+ (T-helper cell type 1 [Th1]) lymphocytes in the lungs of patients with COPD. In both humans and mice, increased Th17 content was seen with smoke exposure, but was not associated with the development or severity of COPD. COPD-affected lung tissue displayed increased Th1 differentiation that was recapitulated in the matching tumor sample. PD-1 (programmed cell death protein 1) expression was increased in tumors of patients with COPD, and the presence of COPD was associated with progression-free survival in patients treated with ICIs. CONCLUSIONS: In patients with COPD, Th1 cell populations were expanded in both lung and tumor microenvironments, and the presence of COPD was associated with longer progression-free intervals in patients treated with ICIs. This has implications for understanding the immune mediators of COPD and developing novel therapies for NSCLC.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Mark NM, Kargl J, Busch SE, et al. Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer. Am J Respir Crit Care Med. 2018. PMID: 28934595. doi:10.1164/rccm.201704-0795OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。